Potential Benefit of Extended Dose Schedules of Human Papillomavirus (HPV) Vaccination in the Context of Limited Resources and COVID-19 Disruptions in Low- and Middle-Income Countries: A Mathematical Modeling Analysis.

34 Pages Posted: 27 Jan 2022

See all articles by Élodie Bénard

Élodie Bénard

Université Laval - CHU de Québec Research Center; Université Laval - Department of Social and Preventive Medicine

Mélanie Drolet

Université Laval - CHU de Québec Research Center

Jean-François Laprise

Université Laval - CHU de Québec Research Center

Mark Jit

London School of Hygiene & Tropical Medicine - Centre for Mathematical Modelling of Infectious Diseases

Kiesha Prem

National University of Singapore (NUS) - Saw Swee Hock School of Public Health; National University Health System (NUHS); London School of Hygiene & Tropical Medicine - Centre for Mathematical Modelling of Infectious Diseases

Marie-Claude Boily

Imperial College London - Medical Research Council Centre for Global Infectious Disease Analysis

Marc Brisson

Université Laval - Department of Social and Preventive Medicine

Date Written: December 17, 2021

Abstract

Background: The WHO Strategic Advisory Group of Experts (SAGE) recommended that an extended interval of 3-5 years between the two doses of the HPV vaccine could be considered to alleviate vaccine supply shortages. However, concerns that girls could be infected between the two doses and reduced vaccination coverage for the 2nd dose have limited the introduction of extended schedules. Using mathematical modeling, we examined the potential impact of these concerns on the population-level effectiveness and efficiency of extended dose HPV vaccination schedules.

Methods: We used HPV-ADVISE, an individual-based, transmission-dynamic model of multi-type HPV infection/disease, calibrated to country-specific data for 4 LMIC (India, Vietnam, Uganda and Nigeria). For the extended dose scenarios, we varied the vaccination coverage of the 2nd dose among girls previously vaccinated and 1-dose vaccine efficacy and duration of protection. We also examined a strategy where 14-year-old girls were vaccinated irrespective of their previous vaccination status. We used 2-dose girls-only vaccination at 9 years old (vaccine=9valent, vaccine-type efficacy=100%, duration of protection=lifetime, coverage=80%) as our comparator. We estimated two outcomes: the relative reduction in the age-standardised cervical cancer (CC) incidence (population-level effectiveness) and the number of cervical cancers averted per 100,000 doses (efficiency).

Results: Our model predicted substantial reductions in CC incidence over 100 years with the 2-dose schedule (78%-84% depending on the country). Predictions were similar for the 5-year extended schedule assuming lower 1-dose efficacy, unless vaccination coverage of the 2nd dose is very low (70%-77% assuming 30% coverage among girls vaccinated at 9 years old). However, vaccinating 70% of 14-year-old girls irrespective of vaccination status would produce substantially greater reduction in CC incidence than the current 2-dose schedule (85%-92%). Efficiency of the extended schedule was greater than the 2-dose schedule, even with a drop in vaccination coverage.

Conclusion: The three concerns are unlikely to have a substantial impact on the population-level effectiveness of extended dose schedules. Hence, extended dose schedules will likely provide similar cervical cancer reductions as 2-dose schedules, whilst reducing the number of doses required in the short-term, providing a more efficient use of limited vaccine resources, and offering a 5-year time window to re-assess the necessity of the 2nd dose.

Note:
Funding: This study was funded by the World Health Organization, a Fonds de recherche du Québec – Santé research scholars award to MB, a foundation scheme grant from the Canadian Institutes of Health Research (FDN-143283), a grant from the Bill & Melinda Gates Foundation (grant number OPP48979), and Compute Canada. MCB acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development (MR/R015600/1).

Declaration of Interests: MB, MD and MJ are members of the Single-dose HPV vaccine evaluation consortium. EB, JFL, KP and MCB declare no competing interests.

Suggested Citation

Bénard, Élodie and Drolet, Mélanie and Laprise, Jean-François and Jit, Mark and Prem, Kiesha and Boily, Marie-Claude and Brisson, Marc, Potential Benefit of Extended Dose Schedules of Human Papillomavirus (HPV) Vaccination in the Context of Limited Resources and COVID-19 Disruptions in Low- and Middle-Income Countries: A Mathematical Modeling Analysis. (December 17, 2021). Available at SSRN: https://ssrn.com/abstract=4016646 or http://dx.doi.org/10.2139/ssrn.4016646

Élodie Bénard

Université Laval - CHU de Québec Research Center ( email )

2214 Pavillon J-A. DeSeve
Quebec, Quebec G1K 7P4
Canada

Université Laval - Department of Social and Preventive Medicine ( email )

Canada

Mélanie Drolet

Université Laval - CHU de Québec Research Center ( email )

2214 Pavillon J-A. DeSeve
Quebec, Quebec G1K 7P4
Canada

Jean-François Laprise

Université Laval - CHU de Québec Research Center ( email )

2214 Pavillon J-A. DeSeve
Quebec, Quebec G1K 7P4
Canada

Mark Jit

London School of Hygiene & Tropical Medicine - Centre for Mathematical Modelling of Infectious Diseases ( email )

Kiesha Prem

National University of Singapore (NUS) - Saw Swee Hock School of Public Health ( email )

12 Science Drive 2
#10-01
117549
Singapore

National University Health System (NUHS) ( email )

1E, Kent Ridge Road
119228
Singapore

London School of Hygiene & Tropical Medicine - Centre for Mathematical Modelling of Infectious Diseases ( email )

London
United Kingdom

Marie-Claude Boily

Imperial College London - Medical Research Council Centre for Global Infectious Disease Analysis

London
United Kingdom

Marc Brisson (Contact Author)

Université Laval - Department of Social and Preventive Medicine

Canada

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
77
Abstract Views
413
Rank
563,673
PlumX Metrics